{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:24:35Z","timestamp":1772627075150,"version":"3.50.1"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2011,7,18]],"date-time":"2011-07-18T00:00:00Z","timestamp":1310947200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0022276","type":"journal-article","created":{"date-parts":[[2011,7,18]],"date-time":"2011-07-18T16:57:04Z","timestamp":1311008224000},"page":"e22276","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Potential Economic Viability of Two Proposed Rifapentine-Based Regimens for Treatment of Latent Tuberculosis Infection"],"prefix":"10.1371","volume":"6","author":[{"given":"David P.","family":"Holland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian D.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol D.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason E.","family":"Stout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2011,7,18]]},"reference":[{"key":"ref1","first-page":"732","article-title":"Isoniazid prophylaxis in contacts of persons with known tuberculosis. Second report.","volume":"92","author":"OB Bush Jr","year":"1965","journal-title":"Am Rev Respir Dis"},{"key":"ref2","first-page":"810","article-title":"Isoniazid prophylaxis in an undeveloped area.","volume":"86","author":"GW Comstock","year":"1962","journal-title":"Am Rev Respir Dis"},{"key":"ref3","first-page":"419","article-title":"The use of isoniazid among household contacts of open cases of pulmonary tuberculosis.","volume":"33","author":"T Egsmose","year":"1965","journal-title":"Bull World Health Organ"},{"key":"ref4","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection.","volume":"49","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"ref5","first-page":"1","article-title":"Guidelines for the investigation of contacts of persons with infectious tuberculosis: Recommendations from the National Tuberculosis Controllers Association and CDC.","volume":"54","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1164\/rccm.200901-0153OC","article-title":"Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.","volume":"179","author":"DP Holland","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1086\/380966","article-title":"Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.","volume":"38","author":"RM Jasmer","year":"2004","journal-title":"Clin Infect Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.7326\/0003-4819-127-12-199712150-00001","article-title":"Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis.","volume":"127","author":"SR Salpeter","year":"1997","journal-title":"Ann Intern Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1164\/rccm.200303-390OC","article-title":"Use of isoniazid for latent tuberculosis infection in a public health clinic.","volume":"168","author":"PA LoBue","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","article-title":"Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months.","volume":"170","author":"D Menzies","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"ref11","first-page":"1445","article-title":"Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.","volume":"283","author":"F Gordin","year":"2000","journal-title":"JAMA"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1164\/rccm.200507-1047OC","article-title":"Rifapentine, Moxifloxacin, or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse Model.","volume":"172","author":"E Nuermberger","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1164\/rccm.200512-1953OC","article-title":"Weekly rifapentine\/isoniazid or daily rifampin\/pyrazinamide for latent tuberculosis in household contacts.","volume":"173","author":"M Schechter","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"ref14","article-title":"The PREVENT TB Study (TB Trials Consortium Study 26): 3 months of once-weekly rifapentine+INH vs. 9 months of daily INH for treatment of latent TB infection: First report of results of a multi-center, randomized clinical trial.;","author":"TR Sterling","year":"2010"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1164\/rccm.200905-0795OC","article-title":"Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.","volume":"180","author":"T Zhang","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"ref16","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis.","volume":"60","year":"1982","journal-title":"Bull World Health Organ"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/oxfordjournals.aje.a112105","article-title":"Frost revisited: the modern epidemiology of tuberculosis.","volume":"101","author":"GW Comstock","year":"1975","journal-title":"Am J Epidemiol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1056\/NEJMsa031667","article-title":"Priorities for the treatment of latent tuberculosis infection in the United States.","volume":"350","author":"CR Horsburgh Jr","year":"2004","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1164\/ajrccm.162.2.9910055","article-title":"Tuberculosis in the homeless. A prospective study.","volume":"162","author":"AR Moss","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1378\/chest.130.6.1712","article-title":"Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin.","volume":"130","author":"A Lardizabal","year":"2006","journal-title":"Chest"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy.","volume":"174","author":"JJ Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(02)09742-8","article-title":"Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.","volume":"360","author":"D Benator","year":"2002","journal-title":"Lancet"},{"key":"ref23","article-title":"Reported tuberculosis in the United States, 2009","year":"2010"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/oxfordjournals.aje.a009463","article-title":"Mathematical model for the epidemiology of tuberculosis, with estimates of the reproductive number and infection-delay function.","volume":"147","author":"EE Salpeter","year":"1998","journal-title":"Am J Epidemiol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/j.1524-4733.2008.00355.x","article-title":"Health State Utilities in Latent and Active Tuberculosis.","volume":"11","author":"N Guo","year":"2008","journal-title":"Value Health"},{"key":"ref26","article-title":"North Carolina Tuberculosis Control Program pharmacy data","author":"D Perry","year":"2011"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1378\/chest.112.1.63","article-title":"A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis.","volume":"112","author":"WJ Burman","year":"1997","journal-title":"Chest"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1164\/ajrccm.160.2.9901049","article-title":"Cost-effectiveness analysis of directly observed therapy for patients with tuberculosis at low risk for treatment default.","volume":"160","author":"DC Snyder","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"ref29","first-page":"931","article-title":"Causes and costs of hospitalization of tuberculosis patients in the United States.","volume":"4","author":"Z Taylor","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/archinte.1995.00430150057006","article-title":"Health-care expenditures for tuberculosis in the United States.","volume":"155","author":"RE Brown","year":"1995","journal-title":"Arch Intern Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","article-title":"Recommendations of the Panel on Cost-effectiveness in Health and Medicine.","volume":"276","author":"MC Weinstein","year":"1996","journal-title":"JAMA"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1164\/rccm.200909-1355OC","article-title":"Revisiting rates of reactivation tuberculosis: a population-based approach.","volume":"182","author":"CR Horsburgh Jr","year":"2010","journal-title":"Am J Respir Crit Care Med"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0022276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T23:07:21Z","timestamp":1560380841000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0022276"}},"subtitle":[],"editor":[{"given":"Pere-Joan","family":"Cardona","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2011,7,18]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2011,7,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0022276","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,18]]}}}